Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Free Cash Flow (2022 - 2025)

Atara Biotherapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$5.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 76.8% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$50.9 million, up 26.13%, while the annual FY2025 figure was -$50.9 million, 26.13% up from the prior year.
  • Free Cash Flow reached -$5.7 million in Q4 2025 per ATRA's latest filing, up from -$9.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$4.0 million in Q3 2024 to a low of -$87.1 million in Q1 2022.
  • Average Free Cash Flow over 4 years is -$36.7 million, with a median of -$34.2 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: surged 92.22% in 2024, then tumbled 145.35% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$61.0 million in 2022, then grew by 17.24% to -$50.5 million in 2023, then surged by 51.38% to -$24.6 million in 2024, then skyrocketed by 76.8% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Free Cash Flow are -$5.7 million (Q4 2025), -$9.8 million (Q3 2025), and -$7.3 million (Q2 2025).